Phase 2 and Phase 3 trials

1 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

ATAI Boosts Investor Visibility With Four Major Healthcare Conferences in June 2026

ATAI plans participation in four major investor conferences in June 2026, showcasing mental health pipeline including Phase 3-bound BPL-003 for treatment-resistant depression.
ATAIinvestor conferencesclinical-stage